生技產業是21世紀的明星產業，政府積極大力投資在生技產業發展。由於生技產業的領域相當廣泛，近年來再生醫學產業最為大家熱烈討論的議題，尤其是幹細胞產業更是再生醫學產業中的新奇技術。然而，在幹細胞產業中，大多公司都僅以幹細胞儲存服務為主，但目前國內外已陸續有一些幹細胞公司開始進行幹細胞新藥的開發，獲得不錯的成果。由於幹細胞新藥與一般新藥開發方式不同，大都新藥是開發化學合成藥物，而幹細胞新藥是以幹細胞為主要成分做成細胞製劑進行植入性治療，所以開發方式和規格不同於一般性。細胞製劑開發屬生技產業中之新興技術，目前在台灣並沒有任何的標竿公司可以成為幹細胞新藥公司的策略典範；因此，國璽幹細胞發展出屬於自己的一套策略經營模式，希望能夠兼顧營業收入及有關幹細胞新藥研發共同目標，讓公司得以永續經營。因此，本研究之目的乃採質化法搭配量化分析方法來探討國璽幹細胞公司的創新經營策略。
本研究以國璽幹細胞公司為研究對象，採用文獻分析法來發掘經營管理的重要策略，並運用迴歸分析法作為研究方法，以對幹細胞經營策略及營運方式有更深的一層研究。另外，本研究針對客戶進行資料分析，發現需求的客戶中，目的幾乎都不同。因此，本研究提出相關建議期望對於學術界、產業界以及政府單位提供幹細胞產業未來發展有所助益。

The biotechnology industry is a star industry in the 21st century, and the government is actively investing in the development of biotechnology industry. As the field of biotechnology industry is quite extensive, in recent years, the regenerative medicine industry is the most enthusiastic discussion of the topic, especially the stem cell industry is the regenerative medicine industry in the novel technology. However, in the stem cell industry, most companies are only stem cell storage services, but at domestic and abroad have been some stem cell companies began to carry out the development of new stem cells, get good results. As the new stem cells and general new drug development methods are different, most of the new drug is the development of chemical synthesis of drugs, and stem cells of new drugs stem cells as the main component of cell preparations for implant treatment, so the development and specifications are different from the general. Cell preparation is a new technology in the biotechnology industry, there is no standard in Taiwan, the company can become a stem cell new drug company strategy model; therefore, the Gwoxi stem cell company to develop their own set of strategic business model, hoping to take into account operating income and related stem cell research and development of new drugs common goal, so that the company can continue to operate. Therefore, the purpose of this study is to adopt the quantitative analysis method to explore the innovation management strategy of Gwoxi stem cell company.
In this study, the paper used to study the important strategies of management and management, and the use of regression analysis as a research method to stem cell management strategies and operating methods have a deeper layer of research. In addition, the purpose of this study is almost the same for customers who need data analysis and find the needs of customers. Therefore, this study suggests that the proposed recommendations will be helpful for the future development of the stem cell industry by academia, industry and government agencies.

山中伸彌博士，2017年，日本諾貝爾獎得主山2017年1月23日日本諾貝爾獎得主山中伸彌博士公開向世人道歉。

王玉祥，2000年，造血幹細胞移植的演進。台灣醫學，4(2)。

江偉芬，2013年，新藥開發技術之日韓前瞻趨勢分析,科技產業資訊室－江偉芬撰稿， 2013年10月1日。

自由經濟日報，2017年，前美國FDA官員陳紹琛(曾是華人圈在美國FDA職務最高官員)所說：台灣生醫界最大的問題就是落後的法規環境。

邱淳芬，2015年，幹細胞新藥產業創新經營成功因素之研究。為出版之碩士論文，私立中華大學企業管理研究所，新竹市。

周中林，2007年，台灣幹細胞產業經營策略之研究-以個案公司為例。未出版之碩士論文，國立台北大學國際財務金融碩士在職專班，新北市。

國璽網頁，2016年，幹細胞新藥GXHPC1-清肝淨，取自http://www.gwoxi.com.tw/index.php/frontend/tmp_cell_drug/view?tmp_cell_drug_id=5

張明富，2003年，後基因體時代之生物技術，教育部顧問室「生物技術科技教育改進計畫」。

張品俞，2011年，再生醫學及組織重組工程的前景與方向。取自http://www.ibmi.org.tw/client/ReportDetail.php?REFDOCTYPID =0kv7fkfs6uh20qiu&REFDOCID=0lnhtssxxtp17eln。

經濟部工業局，2013年，台灣生技產業的範圍2015生技產業白皮書。

楊玉齡(譯)，潘震澤(審閱)，Ann B. Parson(原著)，2006年，海神效應，張老師文化。

鄭信德，2014年，臺灣生技產業效益之分析。臺灣銀行季刊，60(3)，71-95。

劉岱良(主編)，2008 年，喚醒生命力—幹細胞研究與再生醫學。新新聞文化出版，台北縣汐止市。

劉尚志，2001 年，智慧財產權與產業競爭-產業競爭、科寄發展與法律規範之策略思維。競爭政策通訊，5(5)，1-10。

鄧哲明，2013年，新藥的研發流程概論。科學月刊，2013年8月13日，取自http://scimonth.blogspot.tw/2013/03/blog-post_6173.html

錄克雷頓．克里斯汀生，2016年，Clay M. Christensen對「破壞式創新」最具開創性的重大見解。

Aaker, D. A.(1989). ‘ManagingAssets and Skills: The Key to Sustainable Competitive. Advantage’. California Management Review, 31(2): 91–106.

Arojarvi, O.(2001). ‘How to value a biotechnology firms: A study of Current Approaches and Key Value Driver’. Helsinki School of Economics and Business Administration.

Baker, Monya, (2007). ‘Adult cells reprogrammed to pluripotency, without tumors’. Nature Reports Stem Cells.

B.Frederick(2003), Managing Technological Innovation Company, pp.40-45. 7.

Bruestle(2002), The importation and use of embryonic stem cells are prohibited.

Barney, J.B.(1986). ‘Strategic Factor Markets: Expectations, Luck and Business Strategy’. Management Science, 32(10) : 1231–1241.

Barney, J.B. (1986). ‘Organizational Culture: Can It be a Source of Sustained Competitive Advantage?’ Academy of Management Review,11(3) : 656–665.

Fishman, M. C., & Porter, J. A.(2005). ‘Pharmaceuticals: A new grammar for drug discovery’. Nature, 437, 491−493.

Hofer & Schendel.(1978). “Strategy formulation: Analytical concepts” the field's first textbook.

IMS. (2012). The Global Use of Medicines: Outlook Through 2016. IMS Institute for Healthcare Informatics.

J Niosi, TG Bas. (2001).”Small Business Economics.” 17 (1-2), 31-42

John R. Gurdon ,2012 ,The 2012 Nobel Prize for Medicine has been awarded to Drs. John B. Gurdon and Shinya Yamanaka for their creative discoveries in nuclear reprogramming

Lund Stem Cell Center(2003). Sweetland setup January.

Mason C. and Dunnill P.(2008). ‘A brief definition of regenerative medicine’. Regenerative Medicine, 3(1), 1-5

Mansfield, E., and S. Wagner. “Organizational and Strategic Factors(1975). Associated with Probabilities of Success in Industrial R&D.” Journal of Business 48, no. 2:179-198

M. L. Tushman, Lori Rosenkopf.(1992). ’Organizational determinants of technological-change-toward a sociology of technological evolution’. Research in organizational behavior, 14 : 311-347.

Murdick, R. G., Eckhouse, R. H., Moor, R.C., & Zimmerer, T.W. (1980).”Business policy : A framework for analysis (3rd ed.), Colimbus, OH: Grid Publishing

Patrick Sullivan. (1996).“Focus Groups Confirm that MDs, Public Differ on Role of Private Health Care.” Canadian Medical Association Journal 154.

Perez, Carlota.(2001). "Technological change and opportunities for development as a moving target." CEPAL Review75: 109-129.

Poter, M. E.(1980). ‘Competitive Strategy : Techniques for Analyzing Industries and Competitor’. New York : The Free Press.

Porter, M.E..(1990). ‘The Competitive Advantage of Nations’. New York: Free Press, MacMillan.

Takeuchi, Hirotaka and Nonaka, Ikujiro. (1986). ‘The new new product development game’. Harvard. Business Review 64:1:137-146.

Teece, David J.(1996). ‘Firm organization, industrial structure, and technological innovation’. Journal of Economic Behavior & Organization, 31(2) : 193-224.

Till, J.E. & McCulloch, E.A.(1961). ‘A direct measurement of the radiation sensitivity of normal mouse bone marrow cells’. Radiation Res,14 : 213-222

Wernerfelt, B.(1984). ‘The Resource-Based View of the Firm’. Strategic Management Journal, 5(2), 171–180.

World Preview 2015, Outlook To 2020, Evaluate Pharm, 2015 Global biotech market size.